Interestingly, a higher benefit group has been observed with a median OS expectation of 39 months for a subset of patients with NPM1-mutated AML lacking either TP53, FLT3-ITD, KRAS or NRAS variants (18, 32). This evidence concerns the gene NPM1 and acute myeloid leukemia.